Literature DB >> 9013454

Utility of ultrasonography in the diagnosis of autosomal dominant polycystic kidney disease in children.

P A Gabow1, W J Kimberling, J D Strain, M L Manco-Johnson, A M Johnson.   

Abstract

To determine the utility of ultrasonography (US) in diagnosing autosomal dominant polycystic kidney disease (ADPKD) in children, this study examined 106 children who were at 50% risk for the disease. The children underwent a history, physical examination, abdominal US, and gene linkage analysis (GLA) with tightly linked markers for ADPKD1 and ADPKD2 genes. Only ADPKD1 children were studied. A child was considered affected by US if any cysts were detected and affected by GLA if he or she shared the same haplotype as the affected parent. Forty-two children (40%) were considered to be unaffected by both GLA and US. Forty-eight children (45%) were considered affected by both modalities. Only two of these children had a single cyst. Fourteen children (13%) were considered affected by GLA with normal initial US. These children tended to have larger kidneys than children who were unaffected by GLA. Eight of these 14 children had subsequent positive ultrasonograms. Two children had a positive ultrasonogram with GLA showing them to be unaffected; in one of these children, a subsequent ultrasonogram was interpreted to be normal with a medullary pyramid. Thus, overall the false negative rate was 25%, and the false positive rate was 2%. The false negative rate was highest in the children who were 3 months to 5 years of age (38%). Clinicians must understand the utility of US in diagnosing ADPKD in at-risk children and must not interpret a normal study as absence of disease in this population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9013454     DOI: 10.1681/ASN.V81105

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  15 in total

Review 1.  Diagnosis and management of childhood polycystic kidney disease.

Authors:  William E Sweeney; Ellis D Avner
Journal:  Pediatr Nephrol       Date:  2010-10-29       Impact factor: 3.714

2.  Pregnancy outcomes in autosomal dominant polycystic kidney disease: a case-control study.

Authors:  Min Wu; Diping Wang; Ladan Zand; Peter C Harris; Wendy M White; Vesna D Garovic; Cindy A Kermott
Journal:  J Matern Fetal Neonatal Med       Date:  2015-03-10

Review 3.  Polycystic kidney disease: pathogenesis and potential therapies.

Authors:  Vinita Takiar; Michael J Caplan
Journal:  Biochim Biophys Acta       Date:  2010-12-10

4.  Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome.

Authors:  Susan J Back; Savvas Andronikou; Tracy Kilborn; Bernard S Kaplan; Kassa Darge
Journal:  Pediatr Radiol       Date:  2014-10-30

Review 5.  Imaging approaches to patients with polycystic kidney disease.

Authors:  Arlene B Chapman; Wenjing Wei
Journal:  Semin Nephrol       Date:  2011-05       Impact factor: 5.299

6.  Urinary tract infections, VUR, and autosomal dominant polycystic kidney disease.

Authors:  Oren Koslowe; Rachel Frank; Bernard Gauthier; Marcela Vergara; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2003-06-17       Impact factor: 3.714

Review 7.  The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.

Authors:  Bharathi V Reddy; Arlene B Chapman
Journal:  Pediatr Nephrol       Date:  2016-03-31       Impact factor: 3.714

Review 8.  Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD.

Authors:  Dana Rizk; Arlene Chapman
Journal:  Pediatr Nephrol       Date:  2008-02-08       Impact factor: 3.714

Review 9.  Diagnostic Imaging of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Monika Gradzik; Mariusz Niemczyk; Marek Gołębiowski; Leszek Pączek
Journal:  Pol J Radiol       Date:  2016-09-17

10.  Developments in the management of autosomal dominant polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Mir Reza Bekheirnia; Robert W Schrier
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.